Balloon pulmonary angioplasty led to clinical improvements and relatively low complication rates for CTEPH patients in a ...

The National Institutes of Health announced plans to limit publisher fees for publicly funded research by Fiscal Year 2026.

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

The correspondence of Joan B Soriano and Alberto Ruano-Ravina deserves timely praise, highlighting the threat that predatory ...

The CAAT governance board recommends transitioning from the COPD Assessment Test to the CAAT and using it for patients with ...

There is increased risk for pulmonary hypertension in patients with both atrial fibrillation and incident venous thromboembolism.

The pulmonary arterial hypertension market is expected to reach USD 2,080.7 million by 2025 and is expected to steadily grow at a CAGR of 2.3% to reach USD 2,612.0 million by 2035.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

Research shows that digital inhalers equipped with remote monitoring capabilities may aid in predicting and identifying ...

A relatively new therapy used to treat pulmonary arterial hypertension in those with mild to moderate disease was found to be effective at preventing death in those with more advanced disease ...